0001140361-22-005670.txt : 20220216 0001140361-22-005670.hdr.sgml : 20220216 20220216070818 ACCESSION NUMBER: 0001140361-22-005670 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220216 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220216 DATE AS OF CHANGE: 20220216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NU SKIN ENTERPRISES, INC. CENTRAL INDEX KEY: 0001021561 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870565309 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12421 FILM NUMBER: 22641490 BUSINESS ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 BUSINESS PHONE: 801-345-1000 MAIL ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: GREGORY BELLISTON CITY: PROVO STATE: UT ZIP: 84601 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ENTERPRISES INC DATE OF NAME CHANGE: 19980909 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ASIA PACIFIC INC DATE OF NAME CHANGE: 19960919 8-K 1 brhc10034081_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
February 16, 2022
  
 
Date of Report (Date of earliest event reported)
  

 
NU SKIN ENTERPRISES, INC.
  
 
(Exact name of registrant as specified in its charter)
 

Delaware
   001-12421
  
87-0565309
(State or other jurisdiction of incorporation)
  
(Commission File Number)
 
  
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
  
 
(Address of principal executive offices and zip code)
  

 
(801) 345-1000
  
 
(Registrant’s telephone number, including area code)
  

 
N/A
  
 
(Former name or former address, if changed since last report)
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
 NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On February 16, 2022, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2021, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Nu Skin Enterprises’ press release dated February 16, 2022, regarding financial results for the three-month and annual periods ended December 31, 2021.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NU SKIN ENTERPRISES, INC.
 
(Registrant)
   
 
/s/ Mark H. Lawrence
  
 
Mark H. Lawrence
 
Chief Financial Officer
   
Date:  February 16, 2022
  


EX-99.1 2 brhc10034081_ex99-1.htm PRESS RELEASE DATED FEBRUARY 16, 2022
Exhibit 99.1


FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports Fourth Quarter and 2021 Financial Results

Company provides initial 2022 outlook and introduces Nu Vision 2025

PROVO, Utah — Feb. 16, 2022 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced fourth quarter and 2021 results.

Executive Summary
Q4 2021 vs. Prior-year Quarter

Revenue:
    
$673.4 million; (10)%
•          (2)% fx impact or $(11.9) million
Earnings Per Share (EPS):
    
$(0.18) or $1.11 excluding restructuring and impairment charges, compared to $1.40 in Q4 2020
Sales Leaders:
    
61,515; (13)% or 12% compared to 2019
Customers:
    
1,367,559; (12)% or 18% compared to 2019

2021 Annual vs. 2020

Revenue:
    
$2.70 billion; +4%
•          2% fx impact or $66.5 million
Earnings Per Share (EPS):
    
$2.86 or $4.14 excluding restructuring and impairment charges, compared to $3.63 in 2020, or $3.10 in 2019
•          (21)% or 14% excluding restructuring and impairment charges
•          (8)% or 34% excluding restructuring and impairment charges compared to 2019

“For the year, we are encouraged with 4 percent year-over-year revenue growth and 11 percent growth compared to 2019, particularly considering the many COVID-related government restrictions, continued global uncertainty and ongoing transformation of our business,” said Ryan Napierski, Nu Skin President and CEO. “We generated strong demand for our two most recent products, Beauty Focus™ Collagen+ and ageLOC® Meta, as both performed well during the quarter. Our U.S. business grew 32 percent for the year on top of 37 percent in 2020, due in large part to ongoing adoption of our social selling model. Many of our Asian markets, including Mainland China, continue to be impacted by strict lockdowns and restrictions on in-person sales events and promotional activities. However, South Korea is gaining some traction with social commerce and grew 9 percent due to the ageLOC Meta preview and continued demand for our TR90 weight management product.

Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 2
“Looking ahead to 2022, we anticipate another year of growth as we continue our transformation toward becoming the world’s leading integrated beauty and wellness company, powered by our dynamic affiliate opportunity platform. Our Nu Vision 2025 strategy, which we will introduce at our investor event later today, encompasses several key strategic imperatives to accelerate growth, including:  our EmpowerMe personalized beauty and wellness strategy with connected beauty devices; our affiliate-powered social commerce business model; and the expansion of our digital platform. We are confident in our plans as we work toward achieving our vision for the future.”

Q4 2021 Year-over-year Operating Results

Revenue:
    
$673.4 million compared to $748.2 million
•          (2)% fx impact
Gross Margin:
    
74.2% or 75.2% excluding restructuring and impairment charges compared to 74.0%
•          Nu Skin business was 77.9% compared to 76.5%
Selling Expenses:
    
38.7% compared to 38.0%
•          Nu Skin business was 41.0% compared to 40.3%
G&A Expenses:
    
24.7% compared to 24.1%
Operating Margin:
    
3.0% or 11.7% excluding restructuring and impairment charges compared to 11.9%
Other Income / (Expense):
    
$(1.9) million compared to $2.7 million
Income Tax Rate:
    
150.1% or 26.9% excluding restructuring and impairment charges, compared to 19.6%
EPS:
    
$(0.18) or $1.11 excluding restructuring and impairment charges, compared to $1.40

Stockholder Value

Dividend Payments:
    
$18.9 million
Stock Repurchases:
    
$10.0 million
•          $245.4 million remaining in authorization

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 3
Q1 and Full-year 2022 Outlook

Q1 2022 Revenue:
    
$560 to $590 million; (13) to (17)%
•          Approximately (2) to (3)% fx impact
Q1 2022 EPS:
    
$0.65 to $0.75; (18) to (28)%
2022 Revenue:
    
$2.66 to $2.77 billion; (1) to 3%
•          Approximately (1) to (2)% fx impact
2022 EPS:
    
$4.05 to $4.45; +42 to 56% on a reported basis, or (2) to 8% non-GAAP

“We are especially pleased with our adjusted earnings per share of $4.14 for the year and $1.11 for the quarter, driven by gross margin and operational improvements. Full year adjusted EPS results represent annual growth of 14 percent versus 2020 or 34 percent compared to 2019,” added Mark Lawrence, chief financial officer. “During the quarter, we elected to exit our Grow Tech business and re-focus those resources on key strategic initiatives and growth objectives in our core business. We took a one-time pre-tax charge of $58.5 million and anticipate that substantially all the non-cash charges were incurred in the fourth quarter of 2021. As a result of these charges, our reported earnings per share was $2.86 for the year and $(0.18) for the quarter. Our 2022 outlook indicates that we plan to re-invest the bulk of the savings from the exit into technology that will further support our affiliates and drive long-term growth.
 
“Our 2022 revenue guidance is $2.66 to $2.77 billion with EPS of $4.05 to $4.45. First quarter projected revenue is $560 to $590 million with EPS of $0.65 to $0.75. Although our near-term guidance continues to be impacted by global uncertainty, we believe our strategic initiatives will enable stronger growth in the second half. We remain committed to driving operational improvements along the way toward our stated mid-term 13 percent operating income target,” concluded Lawrence.
 
Investor Day
The Nu Skin Enterprises management team will host an investor day event today at noon (ET). To tune in to the webcast and view supplemental materials, visit Nu Skin’s investor relations page at ir.nuskin.com when the event begins. A replay of the event, along with supplemental materials, will be available on the same page through March 2, 2022.

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 4
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a leading beauty and wellness company, powered by a dynamic affiliate opportunity platform. The company helps people live, look and feel their best with products that combine the best of science, technology and nature. Backed by more than 35 years of scientific research, Nu Skin develops innovative products including Nu Skin® personal care, Pharmanex® nutrition and the ageLOC® anti-aging brand which includes an award-winning line of beauty device systems. Nu Skin operates in approximately 50 markets worldwide in the Americas, Asia, Europe, Africa and the Pacific. Rhyz Inc. is the company’s strategic investment arm that includes a collection of technology and manufacturing companies to support growth in the core Nu Skin business. Nu Skin is committed to sustainability, including global initiatives such as transitioning to reduced and sustainable packaging for all products by 2030. The Nu Skin Force for Good Foundation also strives to improve children’s health, education and economic circumstances throughout the world. For more information, visit nuskin.com.
 
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, shareholder value, vision, transformation, initiatives, product pipeline and product introductions, digital tools, customers and sales leaders, affiliates, strategies and initiatives; operational improvements, projections regarding revenue, expenses, operating income, earnings per share, foreign currency fluctuations, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “project,” “outlook,” “guidance,” “remain,” “become,” “plan,” “opportunity,” “expand,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

 •
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;

•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
 
- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 5

•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;

•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•
uncertainties regarding the future financial performance of the businesses the company has acquired;

•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;

•
unpredictable economic conditions and events globally, including trade policies and tariffs;

•
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and

•
continued competitive pressures in the company’s markets.
 
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 6
The following table sets forth revenue for the three-month periods ended December 31, 2021 and 2020 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
December 31,
          
Constant-
Currency
  
   
2021
    
2020
    
Change
    
Change
  
Nu Skin
                        
Mainland China
  
$
130,708
    
$
172,442
      
(24
)%
    
(26
)%
Americas
    
144,000
      
140,586
      
2
%
    
4
%
South Korea
    
92,528
      
90,384
      
2
%
    
8
%
Southeast Asia/Pacific
    
90,313
      
99,589
      
(9
)%
    
(8
)%
EMEA
    
68,066
      
82,656
      
(18
)%
    
(14
)%
Japan
    
63,215
      
73,132
      
(14
)%
    
(6
)%
Hong Kong/Taiwan
    
47,816
      
45,864
      
4
%
    
3
%
Nu Skin other
    
(801
)
    
(391
)
    
(105
)%
    
(105
)%
Total Nu Skin
    
635,845
      
704,262
      
(10
)%
    
(8
)%
Rhyz Investments
                                
Manufacturing
    
36,360
      
43,364
      
(16
)%
    
(16
)%
Grow Tech
    
957
      
567
      
69
%
    
69
%
Rhyz other
    
274
      
—
                  
Total Rhyz Investments
    
37,591
      
43,931
      
(14
)%
    
(14
)%
Total
  
$
673,436
    
$
748,193
      
(10
)%
    
(8
)%

The following table sets forth revenue for the years ended December 31, 2021 and 2020 for each of our reportable segments (U.S. dollars in thousands):

   
Year Ended
December 31,
          
Constant-
Currency
  
   
2021
    
2020
    
Change
    
Change
  
Nu Skin
                        
Mainland China
  
$
568,774
    
$
625,538
      
(9
)%
    
(15
)%
Americas
    
547,755
      
453,022
      
21
%
    
20
%
South Korea
    
354,252
      
326,478
      
9
%
    
6
%
Southeast Asia/Pacific
    
336,651
      
361,627
      
(7
)%
    
(9
)%
EMEA
    
283,200
      
230,246
      
23
%
    
18
%
Japan
    
266,216
      
273,681
      
(3
)%
    
—
  
Hong Kong/Taiwan
    
162,611
      
161,117
      
1
%
    
(2
)%
Nu Skin other
    
1,549
      
(17
)
    
9,212
%
    
9,212
%
Total Nu Skin
    
2,521,008
      
2,431,692
      
4
%
    
1
%
Rhyz Investments
                                
Manufacturing
    
172,120
      
149,339
      
15
%
    
15
%
Grow Tech
    
2,104
      
903
      
133
%
    
133
%
Rhyz other
    
437
      
—
                  
Total Rhyz Investments
    
174,661
      
150,242
      
16
%
    
16
%
Total
  
$
2,695,669
    
$
2,581,934
      
4
%
    
2
%

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 7
The company's Customers and Sales Leaders statistics by segment as of December 31, 2021 and 2020 are presented in the following table:

   
2021
    
2020
    
% Increase
(Decrease)
  
   
Customers
    
Sales Leaders
    
Customers
    
Sales Leaders
    
Customers
    
Sales Leaders
  
Mainland China
    
315,418
      
17,658
      
381,460
      
21,990
      
(17
)%
    
(20
)%
Americas
    
336,564
      
10,340
      
366,688
      
12,754
      
(8
)%
    
(19
)%
South Korea
    
146,354
      
7,108
      
158,953
      
7,059
      
(8
)%
    
1
%
Southeast Asia/Pacific
    
169,601
      
10,386
      
192,622
      
10,588
      
(12
)%
    
(2
)%
EMEA
    
210,414
      
6,124
      
258,587
      
7,063
      
(19
)%
    
(13
)%
Japan
    
122,813
      
5,872
      
128,400
      
6,318
      
(4
)%
    
(7
)%
Hong Kong/Taiwan
    
66,395
      
4,027
      
70,592
      
4,663
      
(6
)%
    
(14
)%
Total
    
1,367,559
      
61,515
      
1,557,302
      
70,435
      
(12
)%
    
(13
)%

“Customers” are persons who purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.

“Sales Leaders” are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 8
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
December 31,
    
Years Ended
December 31,
  
   
2021
    
2020
    
2021
    
2020
  
Revenue
  
$
673,436
    
$
748,193
    
$
2,695,669
    
$
2,581,934
  
Cost of sales
    
173,775
      
194,751
      
675,223
      
658,028
  
Gross profit
    
499,661
      
553,442
      
2,020,446
      
1,923,906
  
                                 
Operating expenses:
                                
Selling expenses
    
260,831
      
284,129
      
1,068,189
      
1,019,494
  
General and administrative expenses
    
166,641
      
180,616
      
666,395
      
646,848
  
Restructuring and impairment expenses
    
51,870
      
—
      
51,870
      
—
  
Total operating expenses
    
479,342
      
464,745
      
1,786,454
      
1,666,342
  
                                 
Operating income
    
20,319
      
88,697
      
233,992
      
257,564
  
Other income (expense), net
    
(1,883
)
    
2,736
      
(1,533
)
    
(1,332
)
                                 
Income before provision for income taxes
    
18,436
      
91,433
      
232,459
      
256,232
  
Provision for income taxes
    
27,666
      
17,966
      
85,193
      
64,877
  
                                 
Net income
  
$
(9,230
)
  
$
73,467
    
$
147,266
    
$
191,355
  
                                 
Net income per share:
                                
Basic
  
$
(0.19
)
  
$
1.44
    
$
2.93
    
$
3.66
  
Diluted
  
$
(0.18
)
  
$
1.40
    
$
2.86
    
$
3.63
  
                                 
Weighted-average common shares outstanding (000s):
                                
Basic
    
49,862
      
50,971
      
50,193
      
52,296
  
Diluted
    
50,801
      
52,403
      
51,427
      
52,765
  

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 9
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
December 31, 2021
    
December 31, 2020
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
339,593
    
$
402,683
  
Current investments
    
15,221
      
21,216
  
Accounts receivable, net
    
41,299
      
63,370
  
Inventories, net
    
399,931
      
314,366
  
Prepaid expenses and other
    
76,906
      
101,563
  
Total current assets
    
872,950
      
903,198
  
                 
Property and equipment, net
    
453,674
      
468,181
  
Operating lease right-of-use assets
    
120,973
      
155,104
  
Goodwill
    
206,432
      
202,979
  
Other intangible assets, net
    
76,991
      
89,532
  
Other assets
    
175,460
      
138,082
  
Total assets
  
$
1,906,480
    
$
1,957,076
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
49,993
    
$
66,174
  
Accrued expenses
    
372,201
      
446,682
  
Current portion of long-term debt
    
107,500
      
30,000
  
Total current liabilities
    
529,694
      
542,856
  
                 
Operating lease liabilities
    
88,759
      
112,275
  
Long-term debt
    
268,781
      
305,393
  
Other liabilities
    
106,474
      
102,281
  
Total liabilities
    
993,708
      
1,062,805
  
                 
Commitments and contingencies
                
                 
Stockholders’ equity:
                
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
    
91
      
91
  
Additional paid-in capital
    
601,703
      
579,801
  
Treasury stock, at cost – 40.7 million and 39.7 million shares
    
(1,526,860
)
    
(1,461,593
)
Accumulated other comprehensive loss
    
(73,896
)
    
(64,768
)
Retained earnings
    
1,911,734
      
1,840,740
  
Total stockholders' equity
    
912,772
      
894,271
  
Total liabilities and stockholders’ equity
  
$
1,906,480
    
$
1,957,076
  

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 10
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Gross margin, operating margin, income tax rate, earnings per share and adjusted earnings per share growth, each excluding impairment and restructuring charges, also are non-GAAP financial measures. Impairment and restructuring charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of impairment and restructuring charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our gross margin, operating margin, income tax rate, earnings per share and earnings per share growth calculated under GAAP, below.

NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share
(in thousands, except per share amounts)
 
   
Three Months Ended
December 31,
    
Years Ended
December 31,
  
   
2021
    
2020
    
2021
    
2020
  
                         
Net income
  
$
(9,230
)
  
$
73,467
    
$
147,266
    
$
191,335
  
Impact of restructuring and impairment:
                                
Restructuring and impairment
    
51,870
      
—
      
51,870
      
—
  
Inventory write-off
    
6,656
      
—
      
6,656
      
—
  
Income tax impact
    
6,933
      
—
      
6,933
      
—
  
Adjusted net income
  
$
56,229
    
$
73,467
    
$
212,725
    
$
191,335
  
                                 
Diluted earnings per share
  
$
(0.18
)
  
$
1.40
    
$
2.86
    
$
3.63
  
Diluted earnings per share, excluding restructuring and impairment impact
  
$
1.11
    
$
1.40
    
$
4.14
    
$
3.63
  
                                 
Weighted-average common shares outstanding (000s):
    
50,801
      
52,403
      
51,427
      
52,765
  

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 11
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Growth Rate Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share
(in thousands, except per share amounts)
 
   
Years Ended
December 31,
  
   
2021
    
2020
    
2019
  
                   
Net income
  
$
147,266
    
$
191,335
    
$
173,553
  
Impact of restructuring and impairment:
                        
Restructuring and impairment
    
51,870
      
—
      
—
  
Inventory write-off
    
6,656
      
—
      
—
  
Income tax impact
    
6,933
      
—
      
—
  
Adjusted net income
  
$
212,725
    
$
191,335
    
$
173,553
  
                         
Diluted earnings per share
  
$
2.86
    
$
3.63
    
$
3.10
  
Diluted earnings per share, excluding restructuring and impairment impact
  
$
4.14
    
$
3.63
    
$
3.10
  
                         
Weighted-average common shares outstanding (000s):
    
51,427
      
52,765
      
55,927
  
                         
2021 annual growth rate
                        
Earnings per share, growth rate
    
(21
)%
                
Earnings per share, growth rate, excluding restructuring and impairment impact
    
14
%
                
                         
2021 growth over 2019
                        
Earnings per share, growth rate
    
(8
)%
                
Earnings per share, growth rate, excluding restructuring and impairment impact
    
34
%
                

NU SKIN ENTERPRISES, INC.
Reconciliation of Gross Margin Excluding Impact of Restructuring and Impairment to GAAP Gross Margin
(in thousands, except per share amounts)
 
   
Three Months Ended
December 31,
    
Years Ended
December 31,
  
   
2021
    
2020
    
2021
    
2020
  
                         
Gross Profit
  
$
499,661
    
$
553,442
    
$
2,020,446
    
$
1,923,906
  
Impact of restructuring and impairment:
                                
Inventory write-off
    
6,656
      
—
      
6,656
      
—
  
Adjusted Gross Profit
  
$
506,317
    
$
553,442
    
$
2,027,102
    
$
1,923,906
  
                                 
Gross margin
    
74.2
%
    
74.0
%
    
75.0
%
    
74.5
%
Gross margin, excluding restructuring and impairment impact
    
75.2
%
    
74.0
%
    
75.2
%
    
74.5
%
                                 
Revenue
  
$
673,436
    
$
748,193
    
$
2,695,669
    
$
2,581,934
  

NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Impact of Restructuring to GAAP Operating Margin
(in thousands, except per share amounts)
 
   
Three Months Ended
December 31,
    
Years Ended
December 31,
  
   
2021
    
2020
    
2021
    
2020
  
                         
Operating income
  
$
20,319
    
$
88,697
    
$
233,992
    
$
257,564
  
Impact of restructuring and impairment:
                                
Restructuring and impairment
    
51,870
      
—
      
51,870
      
—
  
Inventory write-off
    
6,656
      
—
      
6,656
      
—
  
Adjusted operating income
  
$
78,845
    
$
88,697
    
$
292,518
    
$
257,564
  
                                 
Operating margin
    
3.0
%
    
11.9
%
    
8.7
%
    
10.0
%
Operating margin, excluding restructuring and impairment impact
    
11.7
%
    
11.9
%
    
10.9
%
    
10.0
%
                                 
Revenue
  
$
673,436
    
$
748,193
    
$
2,695,669
    
$
2,581,934
  

- more -
Nu Skin Enterprises Reports Fourth Quarter and 2021 Results
Page 12
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Restructuring to GAAP Effective Tax Rate
(in thousands, except per share amounts)
 
   
Three Months Ended
December 31,
    
Years Ended
December 31,
  
   
2021
    
2020
    
2021
    
2020
  
                         
Provision for income taxes
  
$
27,666
    
$
17,966
    
$
85,193
    
$
64,877
  
Impact of restructuring on tax provision
    
(6,933
)
    
—
      
(6,933
)
    
—
  
Provision for income taxes, excluding impact of restructuring
  
$
20,733
    
$
17,966
    
$
78,260
    
$
64,877
  
                                 
Income before provision for income taxes
  
$
18,436
    
$
91,433
    
$
232,459
    
$
256,232
  
Impact of restructuring and impairment:
                                
Restructuring and impairment
    
51,870
      
—
      
51,870
      
—
  
Inventory write-off
    
6,656
      
—
      
6,656
      
—
  
Income before provision for income taxes, excluding restructuring and impairment impact
  
$
76,962
    
$
91,433
    
$
290,985
    
$
256,232
  
                                 
Effective tax rate
    
150.1
%
    
19.6
%
    
36.6
%
    
25.3
%
Effective tax rate, excluding restructuring and impairment impact
    
26.9
%
    
19.6
%
    
26.9
%
    
25.3
%

# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
EX-101.SCH 3 nus-20220216.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nus-20220216_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 nus-20220216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 8$!08%! 8&!08'!P8("A *"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P 1" !: '8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#ZIHHKS+PG MXP^R>)+_ $C4Y/\ 1GN9!!(Q_P!6=Q^4^Q_3^711P\ZT92A]DXL5CJ>%J4X5 M=%-VOYGIM%%4M<=H]%U!XV*NMO(58'!!VGFL(KF:1USERQEVR7,RVS1 M$'(0_>ZCI75]4?M9T MK_"F_N/._M./U>EB.72;2MVN=_1117(>F%%>?_#6]NKK6_$"7-S-,D@ K?$4'1J>S;OM^)RX#%+&TE5@K7;5O M1V)JQKSQ3H-E(8[K6+".0'!4SKD?49XKR:;QG'XR\2_9-4U%M)\.ID^4"0UQ MSP&8=,]?0#WYKV#1=.TJTL8QI%O:I:LN5:%00X]=W?ZU,J?L_B/>Q.7_ %&, M?K-^9]%HE\WU\DOF3:=JEAJ2EM.O;:Z4=3#*KX^N#5RN#^(&E^'((?M,]Y!H MNK8+P7,!V2$^I5>6'J<9]ZSOA9\06UN0:3K++_: !\F?&!.!U!_VL<^_\SV3 M<>>(/+95,.\30NXK=-?BGLUWZKL>FT445D>6%>-Z%X?@\0ZQXGMI<).LK-#+ M_<;>?T/>O9*\V^&O_(V>)?\ KJW_ *&:]'!3E3I59Q=FDOS/"S:C"OB,/2J* MZ;E?_P !+_@3Q#/'<-X>U[,>HVYV1,Y_UBCMGN<=#W'Z]7X@_P"0#J7_ %[2 M?^@FL+QWX8_MFW6\L/W>JVPW1.IP7 YVY]?0U1T3Q0-;\,:I:WO[O5;:UE65 M",%\*1N _F/6B=.-:V(I+K[R[/OZ,*5:>%YL%B'?1\DNZ[/S7XH=\'_^16F_ MZ^G_ /05JAKO_)7M)_ZY+_[-5_X/_P#(K3?]?3_^@K5#7?\ DKVD_P#7)?\ MV:NC_F+K>DOR.#_F687_ !0_,]'HHHKQCZP\W^%G_(?\2?\ 71?_ $)ZZ;QQ M_9_]EQMK4C?VF:YGX6?\A_Q)_UT7_T)ZWO'EU%H M]HFO7$8F73HW,,)Z&9RJJQ^@W?F:]''?[T_E^2.#A1.5"DEO>5K;WYG:SZ:] M>FYFOKZ0V.+GP5?1:3MY'D1MM7WC["H=!NK+0;YIM(F\WPYJ-I->0Q@DB&6+ M!=5ST!!/!Z$5P^@_%W6!K$7]JK;RV,CA9%2/:44]U/M[YKJ;Z".UDU2"%=L2 M7&HE%[+NM48@>@R36+IN.C1]S6P,Z#=*K&W,NC;3MZZJ2=M>UQ^FW%AI;6U[ MJUG-K'BK5(Q<^1%%YC0HWW0 >$4#C/L>U7-2O[*^GMEU[0;K1;KS%-KJ!166 M*3(VY=>G..#Q5+5M>3PI8Z[J\4*RW\T]O9P[^@Q;(P_ 98X[FN8\+_$6_P!= MU)=%\11P7-CJ)^S$K&%9"_ (Q[D>_?-"@Y+F2_KR*AA:M>+Q,8Z+KS-/:]HK M:R6EGN>ZKG:-V-V.<=**AT^*2"PMH9G\R6.)4=_[Q )HKD/E&K.R)Z\V^&O M_(V>)?\ KJW_ *&:])K*TG0+'2KVZNK-'6:Y.Z0ELY.*/%>GZ)8RM]HBENRN(H48,2W;..@JA?_#K0KJ4O&MQ;;CD MK#)Q^1!JQI/@30]-F680/WBE9[YPX#==@S@GZY/Z5T7BC1XM?T&\TV<[5G3 ;& M=K Y4_@0*U**YZU>56JZKW9Z67T?J%.%.D_AZ^>]_O/D?6M%O=!U=[+486BE M1N#V8=B#W!KVS6/^/S5O^N]__P"D<==UKFAZ;KMKY&JVD=P@Y4GAD/J&'(JC M>^%[:YDN'\^9#.TSMT.#)$(SCZ!0?K6DJZG:Y];7SR&+4'45FD[]M;;?<>7? M%3_D7;G_ +"D/_I''5/X-^#+B_U:#6[V-H["U;?%N&/-D'3'L#SGU&/7'K\_ MA32[M66_A-VAG6XV2GY=ZQ+&.!U&%Z'/)K@I>WM#EB M9RSOV>#^K45J]W\N@ZBBBN8^="O.[O6]:\4:UV><8 M]/R]#<;D8=,C%>5_#G4X?#FI:AHNLD6TS2#;(_"DC/!/;/!!Z5WX."Y)U$KR M5K+\W;R/%S6J_:T:,I.,)MW:TV6BOTN:,OAGQ;IZ^?I_B"2ZD'/ERNW/T#9' MYXKO-.^T_8+?[>4-UL'F[!@;N^*L*0R@J00>01WHK"MB)5DE)+[K';A(="?F_P%=PS!5+,0% R23@"O.-? M_P"2NZ1_UQ7_ -GIWB/5KOQ9J;:!X>;%FI_TNZ'W2.XSZ?S^E=E3#>U5.VBY M;M_-GE4,?]7=?FO*7.U&/5Z+1=EW[$EYK^I>)M?73O#,S06,!S/> =?I[>@[ M_P N^MHC!;QQ&224HH!>0Y9OG@<-5IIU<1*\Y;]EY)>7?=G"?$35[[3=8T.*RN7ACG=A(%_BY7 M_$UW=>;?%7_D/>&_]]__ $)*])K3$12H4FEO?\S#!3E+&XF+>B<;>7NG!>,? M$\WAWQA8EB[V,MN!-%GC[[?,!Z__ *J[BUN(KNVCN+:19(9%W(Z]"*\U^(EK M%?>/M#M;E=T,R1HX!QD&1@:=HUY<>!-<.D:H[/H]PVZWG/1/?_$?C]>F>%A5 MH0W=?YHX*.8U,/BZJK?PN:U_P"5V6_D_P &>FUPNG:O?2?$Z^TY[ES9 M1IE8NP^4'^M=TI# $$$'D$=Z\WTK_DL6H_\ 7/\ ]D6N;!Q352Z^R_T._-)R MC*ARNUYK\F>D4445Q'K!6)XC\,:;K\8^VQ$3*,+-&<.OX]_QK6NKB*UMI;BX M<)#$I=V/8#K5;2=6L=6MQ-I]S',N,D*?F7ZCJ*UINI#]Y"ZMU.>O&A6_<5;. M_1_Y'G-Y;:_X!Q<6MS]OT8-AD?HN3W'\/U'?KZ5Z/HNHPZMI=O?6V?*F7< > MH/0@_0Y%87Q(U*ULO"]W#.ZF:X7RXHL\LW0^RZ_ M_P E=TC_ *XK_P"SUUOBSP[;>(M.,$V$G3)AF Y1O\#W%=%2M%4Z=&K\+BOD M[O4XJ&$J2KU\3A_XD)O?9JRNO\F;=%>?^#?$=UI]_P#\(]XES'=1G;!,YX<= M@3W]C^%>@5YE>A*A+EE\GW1]!@\9#%T^>&C6C3W3[,\V^*O_ "'O#?\ OO\ M^A)7I->;?%7_ )#WAO\ WW_]"2O2:Z,3_N]'Y_F<. _W[%>L?_23S?QM_P E M*\._]LO_ $8U=IXDT6VU[3)+.[&,\QR &'9< M^A[?E[5%I7_)8M1_ZY_^R+72^-O#4?B#3_W>([^'YH)>G/\ =/L?TK@OA[+> MR_$&8ZKO^V+"R2;Q@Y4 <_E773<*M.I7CH^5W7GW7J>;B(UL-6H82IK%33C+ MRUT?FNG='L%%%%>(?7$5U;Q75N\%S&LD+C#(PR"*XJ]^&NF/.9;"YN;,_P!U M3N4?3O\ K7=45M1Q%6C_ Y6.3%8'#XNWMX)V^_[]SC='^'VFV5VMU>2S7\R MG*B;[H/T[_B<5V5%%*K7J5G>H[E8;"4<+'EHQLC$O/#=K=^)+;6I)9A,]_6MNBBIE4E-)2>QI3HPI.3@K[[ MF'XA\-6FN7EC<74LZ/:$E!&0 F?<5IT4HSE'X65.G"I;G5[._S04445)9_]D! end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 16, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 16, 2022
Entity Registrant Name NU SKIN ENTERPRISES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-12421
Entity Tax Identification Number 87-0565309
Entity Address, Address Line One 75 West Center Street
Entity Address, City or Town Provo
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84601
City Area Code 801
Local Phone Number 345-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001021561
Title of 12(b) Security Class A Common Stock, $.001 par value
Trading Symbol NUS
Security Exchange Name NYSE
XML 8 brhc10034081_8k_htm.xml IDEA: XBRL DOCUMENT 0001021561 2022-02-16 2022-02-16 false 0001021561 8-K 2022-02-16 NU SKIN ENTERPRISES, INC. DE 001-12421 87-0565309 75 West Center Street Provo UT 84601 801 345-1000 false false false false Class A Common Stock, $.001 par value NUS NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://nuskin.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10034081_8k.htm brhc10034081_ex99-1.htm nus-20220216.xsd nus-20220216_lab.xml nus-20220216_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10034081_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10034081_8k.htm" ] }, "labelLink": { "local": [ "nus-20220216_lab.xml" ] }, "presentationLink": { "local": [ "nus-20220216_pre.xml" ] }, "schema": { "local": [ "nus-20220216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nus", "nsuri": "http://nuskin.com/20220216", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10034081_8k.htm", "contextRef": "c20220216to20220216", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://nuskin.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10034081_8k.htm", "contextRef": "c20220216to20220216", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuskin.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-22-005670-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-005670-xbrl.zip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�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�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end